ORIC Pharmaceuticals announced the selection of the Phase 3 dose for rinzimetostat, a prostate cancer drug, and plans to start the Himalayas-1 global registrational trial in the first half of 2026. Early data show rinzimetostat has a strong safety profile and promising efficacy compared to current treatments for metastatic castration-resistant prostate cancer (mCRPC). The company also reported progress with enozertinib for lung cancer and expects multiple clinical updates later in 2026. With $420 million in cash, ORIC is well-funded to support operations into late 2028 and aims to become a multi-asset oncology company.
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
